Atsena Therapeutics has secured European orphan designation for two gene therapy candidates targeting rare inherited retinal diseases. Infinitopes has...
Lire la suiteLundbeck has secured FDA Fast Track designation for Lu AH69593, an oral orexin 2 receptor agonist being developed for...
Lire la suiteNICE has issued final draft guidance recommending Bayer’s finerenone for adults with symptomatic chronic heart failure and a left...
Lire la suiteThe Regen4HD study has launched the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for...
Lire la suiteNovartis has secured European Commission approval for Itvisma, a one-time gene replacement therapy for a broad group of patients...
Lire la suiteAgomab Therapeutics is preparing to begin dosing patients in its phase 2b NOV-ERA study of ontunisertib for fibrostenosing Crohn’s...
Lire la suite